Hikma Resumes Launch Of Advair Rival
Follows FDA Approval Of ANDA Amendment That Forced Pause
Hikma has restarted launch activities for its generic version of GSK’s Advair respiratory blockbuster in the US, after the FDA gave the go-ahead following approval of an ANDA amendment.
You may also be interested in...
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.
Hikma expects its generics business to hit the top end of its guidance for 2021, after recent launches and an improved product mix drove up its sales and operating margin. Meanwhile, the firm has announced a licensing agreement with Almirall for its Finjuve finasteride brand as the latest in a series of deals.
Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.